Repligen Corp. (RGEN)

131.21 +4.12 (+3.24%) USD  |  NASDAQ  |  Apr 17, 16:00
130.55 -0.66 (-0.50%) Pre-Market: 08:19
More

Repligen SG&A Expense (Quarterly) : 74.36M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for RGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Masimo Corp. 131.30M
Orthofix Medical, Inc. 136.75M
InfuSystem Holdings, Inc. 16.51M
Tandem Diabetes Care, Inc. 113.10M
Plus Therapeutics, Inc. 4.168M